DIVERCHIM CDMO

Executive Summary

DIVERCHIM CDMO is a French contract development and manufacturing organization (CDMO) focused on high-value small molecule drug substances for the pharmaceutical, cosmetics, and specialty chemical industries. Founded in 2015 and based in Paris, the company specializes in niche areas such as orphan drugs, rare diseases, emergency medications, and radiopharmaceutical precursors. With a small team of 1-10 employees and a pre-clinical stage, DIVERCHIM positions itself as a flexible, specialized partner for complex and low-volume active pharmaceutical ingredients (APIs). Its expertise in radiopharmaceutical precursors is particularly relevant given the growing demand for targeted radiotherapies and diagnostics. The company's focus on orphan and rare diseases aligns with favorable regulatory incentives and high unmet medical needs, offering potential for premium pricing and strong margins. However, its small scale and early-stage status present risks related to commercialization, regulatory compliance, and dependency on a limited number of clients. DIVERCHIM's strategic partnerships with biopharmaceutical firms and its ability to navigate complex chemistry will be critical to its growth trajectory.

Upcoming Catalysts (preview)

• Q3 2026Series A Funding Round60% success
• Q3 2026GMP Certification Milestone50% success
• Q3 2026First Major Manufacturing Contract with a Pharma Partner40% success